Clinical effectiveness of dolutegravir in the treatment of HIV/AIDS

Item

http://www.wikidata.org/entity/Q26778450

description

2015 nî lūn-bûn

@nan

2015 թուականին հրատարակուած գիտական յօդուած

@hyw

2015 թվականին հրատարակված գիտական հոդված

@hy

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

name

Clinical effectiveness of dolutegravir in the treatment of HIV/AIDS

@ast

Clinical effectiveness of dolutegravir in the treatment of HIV/AIDS

@en

Clinical effectiveness of dolutegravir in the treatment of HIV/AIDS

@nl

type

Item

label

Clinical effectiveness of dolutegravir in the treatment of HIV/AIDS

@ast

Clinical effectiveness of dolutegravir in the treatment of HIV/AIDS

@en

Clinical effectiveness of dolutegravir in the treatment of HIV/AIDS

@nl

prefLabel

Clinical effectiveness of dolutegravir in the treatment of HIV/AIDS

@ast

Clinical effectiveness of dolutegravir in the treatment of HIV/AIDS

@en

Clinical effectiveness of dolutegravir in the treatment of HIV/AIDS

@nl

P1476

Clinical effectiveness of dolutegravir in the treatment of HIV/AIDS

@en

P2093

Archik Das

http://www.w3.org/2001/XMLSchema#string

Huda Taha

http://www.w3.org/2001/XMLSchema#string

Satyajit Das

http://www.w3.org/2001/XMLSchema#string

P2860

Identification of host proteins required for HIV infection through a functional genomic screen

Structural and Functional Analyses of the Second-Generation Integrase Strand Transfer Inhibitor Dolutegravir (S/GSK1349572)

Dolutegravir interactions with HIV-1 integrase-DNA: structural rationale for drug resistance and dissociation kinetics

Viral dynamics in human immunodeficiency virus type 1 infection

Differential effects of human immunodeficiency virus type 1 capsid and cellular factors nucleoporin 153 and LEDGF/p75 on the efficiency and specificity of viral DNA integration

Pharmacokinetics and safety of S/GSK1349572, a next-generation HIV integrase inhibitor, in healthy volunteers.

Single and multiple dose pharmacokinetics of dolutegravir in the genital tract of HIV-negative women.

Dolutegravir in antiretroviral-experienced patients with raltegravir- and/or elvitegravir-resistant HIV-1: 24-week results of the phase III VIKING-3 study

Contribution of the organic anion transporter OAT2 to the renal active tubular secretion of creatinine and mechanism for serum creatinine elevations caused by cobicistat

Prevention of torsade de pointes in hospital settings: a scientific statement from the American Heart Association and the American College of Cardiology Foundation.

P304

339-52

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

3006433

http://www.w3.org/2001/XMLSchema#string

P356

10.2147/IDR.S68396

http://www.w3.org/2001/XMLSchema#string

P407

English

P478

http://www.w3.org/2001/XMLSchema#string

P577

2015-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26491363

http://www.w3.org/2001/XMLSchema#string

P932

4598225

http://www.w3.org/2001/XMLSchema#string